Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalubuminuric patients with type II diabetes

Hypertension Research

Volumn 23, Issue 3, 2000, Pages 219-226

  Shigihara, Toshikatsu ^a   Sato, Atsuhisa ^a,c   Hayashi, Koichi ^b   Saruta, Takao ^b  

^a Mito Red Cross Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Mito Red Cross Hospital   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium channel blocker; Essential hypertension; Microalbuminuria; Type II diabetes mellitus

Indexed keywords

ALBUMIN; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; IMIDAPRIL; TRANDOLAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0034077284     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.23.219     Document Type: Article

References (31)

1. Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418.
2. Grossman E, Messerli FH: Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304-310.
3. Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.
4. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
5. Hansson L, Zanchetti A, Carruthers G, et al., for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
6. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
7. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-720.
8. Guidelines subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
9. Gall MA, Borch-Johnsen B, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
11. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
12. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regrcssion analysis. Arch Intern Med 1993; 118: 129-138.
13. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-25.
14. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744-750.
15. Maki D, Ma JZ, Lowis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080.
16. Zanetti-Elshater F, Pingitore R, Beretta-Piccdi C, Riesen W, Heinen G: Calcium antagonists for treatment of diabetes-associated hypertension: metabolic and renal effects of amlodipine. Am J Hypertens 1994; 7: 36-45.
17. Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22.
18. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12: 867-873.
19. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-192.
20. Fogari R, Zoppi A, Malamani GD, Lusardi P, Destro M, Corradi L: Effect of amlodipine vs. enalapril on microalbuminuria in hypertensive patients with type II diabetes. Clin Drug Invest 1997; 13 (Suppl 1): 42-49.
21. Velussi M, Brocco E, Frigato F, et al: Effect of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222.
22. Fogari R, Zoppi A, Mugellini A, Lusardi P, Destro M, Corradi L: Effect of benazepril plus amlodipine vs. benazepril alone on urinary albumin excretion in hypertensive patients with type II diabetes and microalbuminuria. Clin Drug Invest 1996; 11 (Suppl 1): 50-55.
23. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963-5967.
24. Hayashi K, Saruta T, Epstein M: The renal hemodynamic effects of calcium antagonists, in Epstein M (ed): Calcium Antagonists. Clinical Medicine (2nd ed.). Hanley & Belfus, 1998, pp393-411.
25. Shultz PJ, Raij L: Effect of amlodipine on mesangial cell proliferation and protein synthesis. Am J Hypertens 1992; 5: 912-914.
26. Carmines PK, Navar LG: Disparate effects of Ca-channel blockade on afferent and efferent arteriolar response to angiotensin II. Am J Physiol 1986; 251: F1043-F1048.
27. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095.
28. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 1991; 303: 81-87.
29. Parving HH, Hommel E, Nielsen MD, Giese J: Effect of captopril on blood pressure and kidney function in normotensive insulin diabetics with microalbuminuria. Br Med J 1989; 299: 533-536.
30. Klahr S, Levey AS, Beck GJ, et al., for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
31. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.